Infection par le Virus de la grippe aviaire ou d'une autre origine animale

Vaccine development and developing countries

Participation of patients in medical research requires that a balance is struck—between anticipated benefits and potential harms of the new treatment being assessed, and with a view to the broader value of evidence accrued for guiding clinical practice and future research. Tensions can arise, however. Research in low-income settings has sometimes been perceived to be of greater potential benefit to those in high-income countries, where a drug may be marketed after licensing.


Mortality dropped, but hospitalizations increased for some in '13-'14 flu season

For the first time since the swine flu pandemic in 2009, influenza A virus pdm09 (pH1N1) predominated in the U.S. during the 2013-2014 flu season. And while this season saw overall lower levels of outpatient illness and death than in those predominated by fellow A virus H3N2, for older adults it was comparatively more severe, a CDC report found.

Influenza Activity — United States, 2013–14 Season and Composition of the 2014–15 Influenza Vaccines

During the 2013–14 influenza season in the United States, influenza activity* increased through November and December before peaking in late December. Influenza A (H1N1)pdm09 (pH1N1) viruses predominated overall, but influenza B viruses and, to a lesser extent, influenza A (H3N2) viruses also were reported in the United States.


Diseases spread in weeks. Epidemic research takes years. This must change

In 1976 a thermos of blood from a Flemish nun who had died in Zaire arrived at the Antwerp lab where Peter Piot, the great microbiologist, was train


Locally made vaccines ‘could boost immunisation efforts’

Mexico and South Africa want to start producing their own vaccines to boost their immunisation programmes, the 67th World Health Assembly (WHA) in Switzerland has heard.
The countries need the WHO and other international agencies to help expand their local manufacturing capacity, a move they hope will lower the cost of vaccines and make their supply more reliable.

New Products Push Influenza Vaccine Market Above $3billion

A new report out from Kalorama Information estimates that influenza vaccines sales rose by 13% to $3.1 billion in 2013. This figure brings the influenza vaccines market up from $2.8 billion in 2012, and back to the sort of levels we saw before the government’s stockpiling 2010 -as a result of this stockpiling, and perhaps over purchasing, the market dropped by 30% in 2011.

Infographic: The Next Great Pandemic

Take a look at these informative infographics on TB, Cholera, HIV, pneumonia, and antimicrobal-resistant diseases from the 


Fludase - Experimental Antiviral Drug for Influenza

NexBio, a US start-up biopharmaceutical company that specialises in developing antiviral agents, has pioneered the development of Fludase (DAS181), an innovative, recombinant drug for the treatment and prevention of influenza.
Fludase completed its initial preclinical development and entered clinical development to determine its efficacy and safety in humans.
In preclinical studies, Fludase displayed potent antiviral activity against clinical influenza isolates, including isolates of the deadly H5N1 strain of avian influenza.